AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31806214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 mg twice daily)
Number of subjects: 2725
Study 31806214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (150 mg twice daily)
Number of subjects: 2725
Study 31806214 — intervention group
Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 2725
Study 29897562 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BV)
Number of subjects: 798
Study 29897562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 798
Study 29897562 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained response or stable disease (post-chemoradiation baseline)
Number of subjects: 798
Study 26516724 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo ELLIPTA DPI (once daily)
Number of subjects: 287
Study 26516724 — intervention group
Group type: COMPARATOR
Intervention: Placebo DISKUS DPI (twice daily)
Number of subjects: 287
Study 26516724 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety assessments
Number of subjects: 287
Study 23418668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (2250 mg/day)
Number of subjects: 39
Study 23418668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 23418668 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Number of subjects: 39
Study 21074355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flexion total knee arthroplasty
Number of subjects: 76
Study 21074355 — intervention group
Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 76
Study 19189275 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical massage treatment (bi-weekly 30-min sessions for 5 weeks)
Number of subjects: 86
Study 19189275 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 86
Study 17697551 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with h-R3 (100 mg weekly intravenous infusion during radiotherapy)
Number of subjects: 35
Study 17697551 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 35
Study 17697551 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with h-R3
Number of subjects: 35
Study 15133322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 mg of beta-cryptoxanthin (esters)
Number of subjects: 12
Study 15133322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 mg of beta-cryptoxanthin (free)
Number of subjects: 12
Study 15133322 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 mg of beta-cryptoxanthin (esters and free)
Number of subjects: 12
Study 11239311 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week intervention exercise regimen designed to increase rapidly available distal strength and balance
Number of subjects: 20
Study 11239311 — intervention group
Group type: COMPARATOR
Intervention: Control exercise regimen
Number of subjects: 20
Study 9163859 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (6 mg deflazacort to 5 mg prednisone ratio)
Number of subjects: 82
Study 9163859 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (control group)
Number of subjects: 82
Study 8201735 — intervention group
Group type: EXPERIMENTAL
Intervention: S boulardii (1 g/d for 4 weeks) with standard antibiotics
Number of subjects: 124
Study 8201735 — intervention group
Group type: COMPARATOR
Intervention: Placebo with standard antibiotics
Number of subjects: 124
Study 3146765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole (10 mg b.i.d. for 7 days)
Number of subjects: 0
Study 3146765 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabeluzole
Number of subjects: 0
Study 3146765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28926204 — intervention group
Group type: EXPERIMENTAL
Intervention: Four nursing clinical decision support interface prototypes
Number of subjects: 60
Study 28926204 — intervention group
Group type: COMPARATOR
Intervention: Control group (HANDS)
Number of subjects: 60
Study 28926204 — intervention group
Group type: EXPERIMENTAL
Intervention: Inexperienced participants (<1 year)
Number of subjects: 60
Study 28495574 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic acromioplasty combined with bursectomy
Number of subjects: 56
Study 28495574 — intervention group
Group type: COMPARATOR
Intervention: Bursectomy alone
Number of subjects: 56
Study 25545321 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (LT)
Number of subjects: 22
Study 25545321 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost (LT) + Narrow band ultraviolet (NB‐UVB)
Number of subjects: 22
Study 25545321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25545321 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow band ultraviolet (NB‐UVB)
Number of subjects: 22
Study 23058209 — intervention group
Group type: COMPARATOR
Intervention: CIDR
Number of subjects: 61
Study 23058209 — intervention group
Group type: COMPARATOR
Intervention: hCG (3300 IU)
Number of subjects: 61
Study 23058209 — intervention group
Group type: COMPARATOR
Intervention: CIDR+hCG
Number of subjects: 61
Study 23058209 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 61
Study 21968664 — intervention group
Group type: EXPERIMENTAL
Intervention: NAFT‐2%
Number of subjects: 334
Study 21968664 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 334
Study 19032529 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-consistent behaviours
Number of subjects: 97
Study 19032529 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-inconsistent behaviours
Number of subjects: 97
Study 19032529 — intervention group
Group type: EXPERIMENTAL
Intervention: Other counsellor behaviours
Number of subjects: 97
Study 21038021 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy (Dexarhinaspray duo and nasal douche)
Number of subjects: 90
Study 21038021 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical therapy
Number of subjects: 90
Study 21038021 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 90
Study 15608312 — intervention group
Group type: EXPERIMENTAL
Intervention: Roentgen irradiation (20 Gy over 2 weeks)
Number of subjects: 6
Study 15608312 — intervention group
Group type: COMPARATOR
Intervention: Sham irradiation (control group)
Number of subjects: 6
Study 12398148 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard preparation with chlorhexidine gluconate home scrubs and preoperative povidone‐iodine
Number of subjects: 49
Study 12398148 — intervention group
Group type: COMPARATOR
Intervention: Standard preparation plus preoperative preparation with 70% alcohol
Number of subjects: 49
Study 9730356 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Skills Training (SST)
Number of subjects: 307
Study 9730356 — intervention group
Group type: EXPERIMENTAL
Intervention: Didactic Training (DT)
Number of subjects: 307
Study 9730356 — intervention group
Group type: COMPARATOR
Intervention: No Training (NT)
Number of subjects: 307
Study 7916020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% levocabastine
Number of subjects: 47
Study 7916020 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle
Number of subjects: 47
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum magnesium hydroxide (10 ml per dose for 10 doses)
Number of subjects: 10
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg per dose for 4 doses)
Number of subjects: 10
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg per dose for 3 doses)
Number of subjects: 10
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (1,000 mg)
Number of subjects: 10
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin (1,000 mg)
Number of subjects: 10
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg)
Number of subjects: 10
Study 2610502 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid (625 mg)
Number of subjects: 10
Study 12449294 — intervention group
Group type: EXPERIMENTAL
Intervention: Three servings of yogurt added to daily diet
Number of subjects: 0
Study 12449294 — intervention group
Group type: COMPARATOR
Intervention: Three servings of a nutrition‐poor snack (control)
Number of subjects: 0
Study 29208626 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin (1500 or 2000 mg)
Number of subjects: 352
Study 29208626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 27903262 — intervention group
Group type: EXPERIMENTAL
Intervention: Test mouthwash (0.25 mg/ml green tea and 7.82 mg/ml Salvadora persica L.)
Number of subjects: 14
Study 27903262 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 14
Study 27903262 — intervention group
Group type: COMPARATOR
Intervention: 0.12% chlorhexidine (control)
Number of subjects: 14
Study 25876344 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 65
Study 25876344 — intervention group
Group type: COMPARATOR
Intervention: Dyne-35 (western medication)
Number of subjects: 65
Study 22578380 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50mg prior to CBT sessions
Number of subjects: 44
Study 22578380 — intervention group
Group type: COMPARATOR
Intervention: Placebo prior to CBT sessions
Number of subjects: 44
Study 20472113 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (OC)
Number of subjects: 30
Study 18332449 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 1000 mL
Number of subjects: 13
Study 18332449 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 1500 mL
Number of subjects: 13
Study 18332449 — intervention group
Group type: EXPERIMENTAL
Intervention: Icodextrin 2500 mL
Number of subjects: 13
Study 15989115 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt test (HUT)
Number of subjects: 61
Study 12914790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dialysed (ND)
Number of subjects: 60
Study 12914790 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodialysed (HD)
Number of subjects: 60
Study 12914790 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis (PD)
Number of subjects: 60
Study 12914790 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 12914790 — intervention group
Group type: EXPERIMENTAL
Intervention: ESRD patients
Number of subjects: 60
Study 10589824 — intervention group
Group type: EXPERIMENTAL
Intervention: High nausea group (9 patients)
Number of subjects: 20
Study 10589824 — intervention group
Group type: COMPARATOR
Intervention: Low nausea group (11 patients)
Number of subjects: 20
Study 8588384 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH administration
Number of subjects: 0
Study 8588384 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 1835318 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath and mesosalpinx blocks (group B)
Number of subjects: 30
Study 1835318 — intervention group
Group type: COMPARATOR
Intervention: Standardised general anaesthetic and rectus sheath block (group A)
Number of subjects: 30
Study 7021447 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (60 mg daily)
Number of subjects: 145
Study 7021447 — intervention group
Group type: COMPARATOR
Intervention: Chlorimipramine (150 mg daily)
Number of subjects: 145
Study 30587610 — intervention group
Group type: EXPERIMENTAL
Intervention: Moisturizing cream containing lipopolysaccharide (LPSp)
Number of subjects: 0
Study 30587610 — intervention group
Group type: COMPARATOR
Intervention: Placebo moisturizing cream
Number of subjects: 0
Study 29064651 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (SS)
Number of subjects: 105
Study 29064651 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 105
Study 29064651 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PTNS + SS
Number of subjects: 105
Study 27105761 — intervention group
Group type: EXPERIMENTAL
Intervention: KNN51 (K-nearest neighbor classifier 51)
Number of subjects: 199
Study 27105761 — intervention group
Group type: COMPARATOR
Intervention: RF15 (15-gene cancer recurrence signature)
Number of subjects: 199
Study 27105761 — intervention group
Group type: COMPARATOR
Intervention: LN20 (20-gene lymph node signature)
Number of subjects: 199
Study 25491041 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive supervision and community mobilization
Number of subjects: 120
Study 25491041 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization alone
Number of subjects: 120
Study 25491041 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 120
Study 25491041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions arm
Number of subjects: 120
Study 25491041 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization arm
Number of subjects: 120
Study 25491041 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions arm (women)
Number of subjects: 120
Study 25491041 — intervention group
Group type: COMPARATOR
Intervention: Control arm (women)
Number of subjects: 120
Study 22431052 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education pathway
Number of subjects: 100
Study 22431052 — intervention group
Group type: COMPARATOR
Intervention: Traditional health education
Number of subjects: 100
Study 20060499 — intervention group
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 1474
Study 17680205 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infiltration of the scalp
Number of subjects: 44
Study 17680205 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine infiltration of the scalp
Number of subjects: 44
Study 16080808 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor-perindopril (+ diuretic-indapamide)
Number of subjects: 1520
Study 12061605 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow tempo condition
Number of subjects: 240
Study 12061605 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast tempo condition
Number of subjects: 240
Study 12061605 — intervention group
Group type: EXPERIMENTAL
Intervention: No tempo condition
Number of subjects: 240
Study 11136842 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (ERT)
Number of subjects: 168
Study 11136842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 11136842 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (higher dose)
Number of subjects: 168
Study 11136842 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (lower dose)
Number of subjects: 168
Study 9848309 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoosmotic swelling test
Number of subjects: 0
Study 9848309 — intervention group
Group type: EXPERIMENTAL
Intervention: Water test
Number of subjects: 0
Study 9848309 — intervention group
Group type: EXPERIMENTAL
Intervention: Eosin-Y staining
Number of subjects: 0
Study 9848309 — intervention group
Group type: EXPERIMENTAL
Intervention: None of the membrane integrity tests
Number of subjects: 0
Study 7978777 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized anxiety disorder patients
Number of subjects: 0
Study 7978777 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study 7978777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 2542549 — intervention group
Group type: EXPERIMENTAL
Intervention: ANP infusion at 0.1 microgram/min with enalaprilat (5 micrograms/min)
Number of subjects: 6
Study 2542549 — intervention group
Group type: COMPARATOR
Intervention: ANP infusion at 0.1 microgram/min with placebo (saline)
Number of subjects: 6
Study 2542549 — intervention group
Group type: EXPERIMENTAL
Intervention: First ANP infusion (0.1 microgram/min) before placebo
Number of subjects: 6
Study 2542549 — intervention group
Group type: EXPERIMENTAL
Intervention: First ANP infusion (0.1 microgram/min) before enalaprilat
Number of subjects: 6
Study 796940 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 0
Study 796940 — intervention group
Group type: COMPARATOR
Intervention: Phenylbutazone
Number of subjects: 0
Study 31498264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular TXA only (simultaneous TKA)
Number of subjects: 310
Study 31498264 — intervention group
Group type: COMPARATOR
Intervention: Combined IV and intraarticular TXA (simultaneous TKA)
Number of subjects: 310
Study 31498264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular TXA only (staged TKA)
Number of subjects: 310
Study 31498264 — intervention group
Group type: COMPARATOR
Intervention: Combined IV and intraarticular TXA (staged TKA)
Number of subjects: 310
Study 31498264 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular TXA only and Combined IV and intraarticular TXA
Number of subjects: 310
Study 30573004 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of prednisolone
Number of subjects: 14
Study 27885448 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs): IFNB1-a SC, IFNB1-b, GA
Number of subjects: 161
Study 27885448 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 161
Study 27885448 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies (DMTs)
Number of subjects: 161
Study 27885448 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNB and GA
Number of subjects: 161
Study 25968495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine with carvedilol
Number of subjects: 5960
Study 25968495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine with bisoprolol
Number of subjects: 5960
Study 25968495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine with metoprolol
Number of subjects: 5960
Study 25968495 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine with nebivolol
Number of subjects: 5960
Study 25968495 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol with placebo
Number of subjects: 5960
Study 23651816 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of bone marrow mesenchymal stem cells (BMSCs); n=21
Number of subjects: 43
Study 23651816 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment; n=22
Number of subjects: 43
Study 21764225 — intervention group
Group type: EXPERIMENTAL
Intervention: Without peritonisation
Number of subjects: 252
Study 21764225 — intervention group
Group type: COMPARATOR
Intervention: With peritonisation
Number of subjects: 252
Study 19290426 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass fiber‐reinforced post core
Number of subjects: 100
Study 19290426 — intervention group
Group type: COMPARATOR
Intervention: Metal cast post core
Number of subjects: 100
Study 16945045 — intervention group
Group type: EXPERIMENTAL
Intervention: TrimSpa (ephedra 15 mg and caffeine 60 mg, 3 times/day for 7 days)
Number of subjects: 13
Study 16945045 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, 3 times/day for 7 days)
Number of subjects: 13
Study 16945045 — intervention group
Group type: EXPERIMENTAL
Intervention: TrimSpa
Number of subjects: 13
Study 14628097 — intervention group
Group type: EXPERIMENTAL
Intervention: [(11)C]choline PET
Number of subjects: 19
Study 11406335 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg peroral ketoprofen
Number of subjects: 6
Study 11406335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg peroral ketoprofen
Number of subjects: 6
Study 11406335 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg topical 2.5% ketoprofen gel
Number of subjects: 6
Study 11406335 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg topical ketoprofen gel
Number of subjects: 6
Study 11406335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 11406335 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 6
Study 9246958 — intervention group
Group type: EXPERIMENTAL
Intervention: pH
Number of subjects: 100
Study 9246958 — intervention group
Group type: EXPERIMENTAL
Intervention: DAO
Number of subjects: 100
Study 9246958 — intervention group
Group type: EXPERIMENTAL
Intervention: IGFBP1
Number of subjects: 100
Study 7920940 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU486) 600 mg
Number of subjects: 46
Study 7920940 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7920940 — intervention group
Group type: COMPARATOR
Intervention: Control group (Placebo)
Number of subjects: 46
Study 3521444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 g twice daily for 3 days
Number of subjects: 0
Study 3521444 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30977581 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapists' self-audit of performance
Number of subjects: 8
Study 30977581 — intervention group
Group type: COMPARATOR
Intervention: Training facilitator's audit of performance
Number of subjects: 8
Study 30977581 — intervention group
Group type: EXPERIMENTAL
Intervention: Person-centred practice principles
Number of subjects: 8
Study 30977581 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change techniques
Number of subjects: 8
Study 30264456 — intervention group
Group type: EXPERIMENTAL
Intervention: QLV-based implant strategy
Number of subjects: 250
Study 30264456 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 250
Study 25581159 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg) 100 U/mL, subcutaneously, at doses of 0.4-0.8 U/kg for 6-12 days
Number of subjects: 195
Study 25581159 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 195
Study 25194583 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral sleep problems
Number of subjects: 195
Study 25194583 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurring internalizing and externalizing comorbidities
Number of subjects: 195
Study 25194583 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater ADHD symptom severity
Number of subjects: 195
Study 25194583 — intervention group
Group type: EXPERIMENTAL
Intervention: Poorer caregiver mental health
Number of subjects: 195